Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNAâ˘) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source
No articles found.
We are a leading, rapidly growing synthetic biology company that has developed a d...
We are a leading, rapidly growing synthetic bio...
Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused ...
Millendo Therapeutics is a late-stage biopharma...
PLUS THERAPEUTICS is a clinical-stage pharmaceutical company focused on making a p...
PLUS THERAPEUTICS is a clinical-stage pharmaceu...
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company develop...
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stag...
Acacia Diversified Holdings, Inc., is an emerging hemp company, through its wholly...
Acacia Diversified Holdings, Inc., is an emergi...
KalVista is a pharmaceutical company focused on the discovery, development and com...
KalVista is a pharmaceutical company focused on...
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying a ...
SpringWorks Therapeutics is a clinical-stage bi...
At Affimed, we are committed to improving outcomes for patients with cancer. Our s...
At Affimed, we are committed to improving outco...
Syros is redefining the power of small molecules to control the expression of gene...
Syros is redefining the power of small molecule...
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with ...
Arena Pharmaceuticals is driven to deliver nove...
Join the National Investor Network and get the latest information with your interests in mind.